Rapamycin · the evidence
Rapamycin: what the evidence actually shows
Rapamycin extends mouse lifespan by 9% to 14% when dosing starts in mid-life, and no human trial has ever used lifespan as an endpoint. Both halves of that sentence are load-bearing.
On this page
Most coverage picks a side. This page reports both, and shows you how to tell which question a given claim is answering.
The two-sentence version
The drug reliably extends lifespan in mice and across other tested species, and the effect survives even when dosing starts in mid-life.[1] In humans it has been shown to affect immune response and biomarkers in small trials, and it has never been tested against lifespan or any hard clinical endpoint of aging.
Everything else on this page is detail underneath those two sentences.
What is rapamycin?
Rapamycin, generic name sirolimus, is a drug produced by the soil bacterium Streptomyces hygroscopicus and FDA-approved to prevent organ transplant rejection.[6] It works by inhibiting mTOR, a central growth-signaling pathway, and it extends lifespan across tested species from yeast to mice without ever having been shown to do so in humans.
The compound was collected on Rapa Nui in the 1960s, which is where the name comes from.[10] Its second career began decades later, when several laboratories independently found that inhibiting mTOR slowed aging in model organisms.
Show the numbers as a table
| When | Event | Detail |
|---|---|---|
| 1960s | Found on Rapa Nui | soil bacterium sample |
| 2009 | Late-life mouse gain | Interventions Testing |
| 2014 | Vaccine response trial | rapalog, older adults |
| 2019 | Universal drug essay | Blagosklonny opinion |
| 2025 | PEARL misses endpoint | visceral fat unchanged |
Its claimed benefits, from autophagy and mitophagy to reduced inflammation, all follow from that one mechanism. There is no approved aging indication anywhere, and every use aimed at slowing aging is off-label.
How we weigh the rapamycin literature
- Every figure carries its conditions. Which species, initiated when, on what schedule, measured how.
- We name the molecule. Several headline human results used a rapalog rather than the parent drug, and we say so.
- We report the strongest case against. A page that only cites enthusiasts is an advertisement.
- We name who paid. When trial authors work for a company that sells the protocol, that belongs next to the result.
- No product, no commission. We sell no prescription drug and hold no clinic relationships.
We have no clinician on staff and claim no authority beyond careful reading of sources you can check yourself.
Why the top two sources on this topic disagree
Search this topic and the first organic result is Blagosklonny's heavily cited opinion piece, arguing the drug extends lifespan in all tested models from yeast to mammals and calling it a universal anti-aging drug.[2]
The second is a 2025 assessment from Aging-US stating that human trials have not yet shown the drug can safely or effectively slow aging or extend lifespan.[3]
| Claim | Domain | Status |
|---|---|---|
| Extends lifespan in mice and other tested models | Yeast, worms, flies, mice | Well supported and replicated[7] |
| Improves an aging-related human outcome | Humans, surrogate endpoints | Preliminary, small trials, often using rapalogs[8] |
| Extends human lifespan | Humans, hard endpoint | Never tested |
Neither source is wrong. The first is a claim about model organisms, where the evidence is strong and replicated; the second is a claim about humans, where the relevant trial has not been run.
When two credible people seem to contradict each other on this topic, check which row they are talking about. Almost every apparent disagreement dissolves there.
The evidence ladder, species by species
| Species | What was measured | Result |
|---|---|---|
| Yeast, worms, flies | Lifespan | Extension, replicated across laboratories |
| Mice | Lifespan, from mid-life | 9% to 14% extension from mid-life administration, plus delayed age-related disease[1] |
| Dogs | Cardiac function, 10 weeks | Two measures improved, one missed significance; lifespan trial unfinished |
| Humans | Immune response, biomarkers, safety | Preliminary signals; no lifespan endpoint has ever been used |
The dog row is the closest thing to a bridge, and it is why the canine lifespan trial matters more to this field than its size suggests.
Strong in animals · unmeasured in humansThe mouse figure everyone quotes, and the condition they drop
The 9% to 14% figure applies specifically to mid-life administration, not to lifelong dosing.[1]
That condition is not a footnote. An intervention that only works from birth is a curiosity; one that still works when started late is a candidate for actual medicine, because humans do not get to start at birth.
What the number means without the timing
Quoted without the timing, the number is decoration. Quoted with it, it is the reason anyone is interested.
Does rapamycin increase lifespan?
In mice, yes, repeatedly and across independent laboratories, including the Interventions Testing Program built specifically to weed out results that do not replicate.[7] Those mice began treatment at 20 months, roughly 60 in human years, which is the late start the researcher below is describing.
What is known in humans
In humans, nobody knows. No trial has used lifespan as an endpoint, and none is currently running that could.
That distinction matters more than it sounds. "No evidence it extends human life" describes what has been measured, not a trial that ran and failed.
What human trials have actually measured
Immune function after vaccination in older adults is the most cited human result, from the Mannick trials, and it is a genuine randomized finding.[8] The PEARL trial and other small randomized studies have since looked at biomarkers, body composition and safety in healthy adults.[9]
A systematic review in The Lancet Healthy Longevity summarized the drug and its derivatives across human studies.[4] Every one of these trials measures a surrogate: useful, chosen carefully, and still not the thing the headline claims.
The best weekly-dosing trial missed its own question
PEARL is the trial most often cited as human support for the weekly protocol, so its design matters. It gave healthy adults 5 or 10 mg of compounded sirolimus weekly for 48 weeks against placebo, and its pre-specified primary outcome, visceral fat, did not change (p=0.942, per the 2025 PEARL report).[9]
The positive findings, better lean mass and less pain, appeared only in women on the higher dose, which is a subgroup result that needs replication. The authors also worked for AgelessRx, a telehealth company that prescribes the drug. Treat PEARL as evidence the protocol was tolerated for a year, not as evidence it works.
- What this does not say
- Compounded rapamycin, which delivers less drug per milligram, may have under-dosed participants; subgroup findings need replication.
The rapalog substitution nobody flags
Several headline human aging results used everolimus or another rapalog rather than the parent drug itself.
Rapalogs are chemical derivatives that share the mTOR mechanism with different pharmacokinetics. Results may transfer between them; that is a reasonable assumption, and it is still an assumption rather than a finding.
- Check the molecule. Before you cite a human result, confirm whether the trial gave sirolimus or a derivative.
- Check the formulation. Compounded versions may deliver less drug per milligram than the branded tablet.
What people actually take, according to the largest survey
In the published survey of off-label users, 95% of participants reported using it for healthy longevity or anti-aging, and the most common regimen was 6 mg once per week.[4]
That is a description of behavior. It tells you what a self-selected group of people do, and nothing at all about whether the rapamycin longevity case holds up.
Why we report the survey anyway
We report it because the number is informative about the field and routinely quoted as though it were evidence. The dosing literature itself is covered in the dosing evidence in detail.
Why the schedule matters more than the number
Here is a coincidence worth sitting with. The common regimen from that survey is 6 mg weekly, and in an oncology dose-finding study the maximum tolerated daily oral dose was also 6 mg.[5]
Show the numbers as a table
| Measure | Value |
|---|---|
| Common off-label regimen | 6 mg a week |
| Oncology daily maximum | 6 mg daily (42 mg a week) |
Same number, roughly a sevenfold difference in weekly exposure. At the daily maximum, at least 20% of patients experienced hyperglycemia, hyperlipidemia and elevated transaminases.
Why intermittent dosing is the hypothesis
Intermittent dosing is the entire hypothesis: inhibit mTOR enough to trigger maintenance processes, then let signaling recover before immunosuppressive effects accumulate. The schedule is not a detail attached to the dose; it is the idea.
What happens if I take rapamycin every day?
Daily dosing is the transplant and oncology pattern, and it is designed to suppress mTOR continuously.
The dose-finding study above is the clearest picture of what that costs at the ceiling: hyperglycemia, hyperlipidemia and elevated transaminases in at least a fifth of patients.[5] Continuous inhibition is also where the muscle protein synthesis concern lives, since mTOR is central to building muscle.
Low doses in healthy people still move measurable markers
The idea that a small dose is too small to matter is not what the few trials show. In one, 25 adults aged 70 to 95 were randomized to 1 mg daily or placebo for 8 weeks (11 on the drug, 14 on placebo, per Kraig 2018), and the treated group saw albumin fall while triglycerides and HbA1c rose.[11]
Trials of the rapalog everolimus at higher doses also recorded more self-reported anxiety. A 2025 review of this small literature, fewer than a dozen trials, concluded that human data have not established that the drug delays aging. For a healthy adult, that means accepting measured metabolic changes for a benefit no human trial has shown.
- What this does not say
- The trials are small (Kraig: 11 treated, 14 placebo), short, and used varied doses and rapalogs, so neither harm nor benefit is well estimated; weekly dosing may behave differently from daily.
Frequency is a clinical decision. We report what studies administered, and we issue no schedules.
What is the downside of rapamycin?
Mouth ulcers, sometimes reported as stomatitis, and raised blood lipids are the most consistently reported effects across the human literature.[4] Infection risk rises with immunosuppression at higher exposures, which is the mechanism working as designed in its licensed use.
About 15% of people taking rapamycin 6 mg once a week will develop mouth sores.
Interstitial lung inflammation and anemia appear at higher doses. The muscle question remains open.
The missing long-term record
The largest downside is the shape of the record rather than any single effect: long-term data in healthy people does not exist, because nobody has followed healthy people on a weekly low dose for a decade. The detail sits in the full side-effect picture.
What is better than rapamycin?
The question needs a qualifier before it means anything: better at what, measured in which species, at what cost.
| Intervention | Animal lifespan evidence | Human evidence |
|---|---|---|
| Sirolimus | Strongest in the field | Surrogate endpoints only |
| Metformin | Weaker and contested | Decades of safety data, large observational literature |
| Caloric restriction | Strong across species | Biomarker trials, poor adherence in practice |
| Exercise and sleep | Consistent | The largest human evidence base of anything here |
The comparison people usually want is with how metformin compares, and the two have close to inverted evidence profiles.
What would settle this
Three things would move this page materially, and we would rather say so in advance than adjust quietly later.
- A randomized human trial with a hard clinical endpoint. Not a biomarker, and adequately powered.
- Replication of the immune function findings using the parent drug itself rather than a rapalog.
- The canine lifespan trial reporting. It is the nearest available proxy for a mammal that shares our environment.
Absent those, the honest position stays where it is: the best-supported hypothesis in geroscience, still a hypothesis in humans.
Nobody is going to spend 200 million dollars to do a clinical study on a drug if it's not their drug.
Read the quote as an explanation of the gap, not a verdict on the drug: an unfunded trial and a failed trial are different things.
How to read the next rapamycin headline
- Which species, and how many? Twenty-four animals is a pilot, not a proof.
- Initiated when, and for how long? Mid-life initiation is what makes a result interesting.
- Parent drug or a rapalog? The substitution is common and rarely disclosed.
- Lifespan, or a surrogate standing in for it? Almost always the latter.
- Did the primary outcome move? A subgroup win after a missed endpoint is a lead, not a result.
- Who employed the authors? A conflict does not void a trial, and it belongs in the summary.
Six questions will let you assess most claims in this field faster than any summary, including this one.
Where to go next
This page is the hub. The detail lives in the pages beneath it: what it costs and how people access it, the dosing evidence, the side-effect profile, the topical form, and the canine trial that may report before any human one does.
Informational only, not medical advice
If a large randomized human trial reports on a clinical endpoint, this page will change and say when. Until then the summary is short: the strongest animal lifespan data in geroscience, a real mechanism, a safety record drawn from a different population on a different schedule, and an unmeasured question at the center of it.
Frequently asked questions about rapamycin
Does rapamycin increase lifespan?
In mice, yes, repeatedly and across independent laboratories: administration started in mid-life extends mouse lifespan by roughly 9 to 14 percent. In humans, nobody knows, because no trial has ever used lifespan as an endpoint. That is a gap in what has been measured, not a failed result.
What is the downside of rapamycin?
Mouth ulcers and raised blood lipids are the most consistently reported effects. Infection risk rises with immunosuppression at higher exposures, and continuous mTOR inhibition raises a real question about muscle protein synthesis. The largest downside is simply that long-term data in healthy people does not exist.
What is better than rapamycin?
It depends what you are measuring: metformin has more accumulated human data and a weaker animal signal. Exercise and sleep have the largest human evidence base of any intervention discussed in longevity. No supplement substitutes for mTOR inhibition, whatever the label says.
What happens if I take rapamycin every day?
Daily dosing is the transplant and oncology pattern, designed to suppress mTOR continuously. In an oncology dose-finding study the maximum tolerated daily dose was 6 mg, with hyperglycemia, hyperlipidemia and elevated transaminases in at least 20% of patients. Frequency is a prescriber's decision.
Is rapamycin FDA approved for anti-aging?
No. The FDA approval covers prevention of organ transplant rejection. There is no approved aging or longevity indication anywhere, so every longevity use is off-label and no regulator has established a standard anti-aging dose.
Did the human trials use rapamycin or a derivative?
Several of the headline human aging results used rapalogs, chemical derivatives such as everolimus, rather than the parent drug itself. Rapalogs share the mTOR mechanism with different pharmacology. Findings may transfer between them, and that is an assumption rather than a demonstrated result.
Why do experts disagree about rapamycin?
Largely because they are answering different questions: the strongest published case argues it extends lifespan in every tested model from yeast to mammals, which is accurate. The strongest counterweight notes that human trials have not shown it slows aging, which is also accurate. Model organisms and humans are separate evidentiary worlds here.
How much longer do mice live on the drug?
Roughly 9 to 14 percent when administration begins in mid-life. That timing condition matters more than the percentage: the striking part of the result is that starting late still produced a gain, which is the central argument of geroscience.
Has any human trial measured lifespan?
No. Human trials have measured immune response to vaccination, biomarkers and safety endpoints. A human lifespan trial would take decades and cost far more than anyone has committed, so the honest phrase is unmeasured rather than disproven.
What dose do people actually take for longevity?
In the largest published survey of off-label users, the most common regimen was 6 mg once per week, and 95% of respondents said they were taking it for healthy longevity. That describes behavior, not efficacy, and we report it as such.
Why weekly instead of daily?
The hypothesis is that intermittent inhibition captures the maintenance benefits while allowing mTOR signaling to recover between doses, avoiding the continuous suppression that drives immunosuppression. The schedule is the hypothesis, not an implementation detail.
Does sirolimus affect muscle growth?
It is a legitimate open concern. mTOR is central to muscle protein synthesis, so continuous inhibition would be expected to interfere with building muscle. Whether intermittent dosing avoids that is one of the more consequential unanswered questions in the field.
What foods contain rapamycin?
None. It is a macrolide produced by the soil bacterium Streptomyces hygroscopicus, collected on Rapa Nui. It is not present in any food, plant or botanical extract, and no supplement contains it whatever the marketing suggests.
Is there a supplement version I can buy?
No legitimate one. It is a prescription drug, so any over-the-counter product marketed as a supplement version either does not contain it or is not being sold lawfully. Products described as natural alternatives contain different compounds entirely.
Is sirolimus safe for healthy people long term?
Unknown, and that is the honest answer. The safety record comes from transplant patients on continuous immunosuppressive dosing and from short trials in older adults. Neither tells you what a decade of weekly low-dose use does to a healthy person.
How does sirolimus compare with metformin?
Roughly inverted evidence profiles. Metformin has decades of human safety data and a large observational literature, with a weaker and contested animal lifespan signal. Sirolimus has the strongest animal lifespan evidence in geroscience and much thinner human data.
How would I know if the evidence changed?
Watch for three things: a randomized human trial with a hard clinical endpoint, replication of the immune findings using the parent drug rather than a rapalog, and the canine lifespan trial reporting. Any of those would move this page substantially.
What would make you stop urging caution?
An adequately powered randomized human trial showing benefit on a clinical endpoint, not a biomarker. Short of that, the honest position stays what it is: the best-supported hypothesis in the field, and still a hypothesis in humans.
Sources and how we checked them
11 sources, all link-checked; oldest check
- Rapamycin for longevity: the pros, the cons, and future perspectives. Roark KM, Iffland PH. Frontiers in Aging 2025;6:1628187.Peer-reviewed review, cited 31 times.Verified Sep 15, 2026
- Rapamycin for longevity: opinion article. Blagosklonny MV. Aging (Albany NY) 2019;11(19):8048-8067 (cited 258).The strongest published pro-rapamycin position: argues it extends lifespan in all tested models from yeast to mammals and calls it a universal anti-aging drug.Verified Sep 15, 2026
- Rapamycin shows limited evidence for longevity benefits in healthy adults. Aging-US news room, Sep 2025.Publisher blocks automated checks · last tried Sep 15, 2026
- Targeting aging with rapamycin and its derivatives in humans: a systematic review. Lee DJW et al. The Lancet Healthy Longevity 2024.Systematic review, cited 189 times.Publisher blocks automated checks · last tried Sep 15, 2026
- Pharmacodynamic-guided dose-finding study of rapamycin in adult patients with solid tumors. Journal of Clinical Oncology, via PMC2654371.Maximum tolerated dose of DAILY oral rapamycin was 6 mg; toxicities in at least 20% of patients included hyperglycemia, hyperlipidemia and elevated transaminases.Verified Sep 15, 2026
- Sirolimus - NCI Drug Dictionary. National Cancer Institute.Entity reference for sirolimus as the generic name of rapamycin.Verified Sep 15, 2026
- Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Harrison DE et al. Nature 2009;460:392–395.9–14% mouse lifespan extension started mid-life.Verified Sep 15, 2026
- mTOR inhibition improves immune function in the elderly. Mannick JB et al. Science Translational Medicine 2014;6(268):268ra179.RAD001 (rapalog) improved influenza-vaccine response ~20% in older adults.Verified Sep 15, 2026
- Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Moel M et al. Aging (Albany NY) 2025;17(4):908–936.48-week RCT, 5/10 mg weekly; safe, no visceral-fat change; authors employed by AgelessRx; note conflict.Verified Sep 15, 2026
- Sirolimus. Wikipedia.Verified Sep 15, 2026
- A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort. Kraig E et al. Experimental Gerontology 2018;105:53–69.n=25, aged 70–95, 1 mg daily 8 weeks; tolerable, but measurable red-cell index changes.Verified Sep 15, 2026
Every link above is re-requested on a schedule by an automated checker; the date shown is when it last answered. Publishers that block automated requests are marked as such rather than reported broken. Our editorial standards explain how a source gets cited here in the first place.
Filed by the Rapamycin.store evidence desk. Each source is re-checked when the page is reviewed.
Keep weighing the evidence
Rapamycin.store publishes sponsored and guest posts on an aged, topically-relevant domain, and offers display advertising. Tell us what you want to promote and we'll send our current options.